Increased risk for NAION seen among participants with T2D, overweight/obesity receiving semaglutide vs non-GLP1-RA meds. HealthDay News — Semaglutide is associated with nonarteritic anterior ...

Increased risk for NAION seen among participants with T2D, overweight/obesity receiving semaglutide versus non-GLP1-RA meds. (HealthDay News) — Semaglutide is associated with nonarteritic ...

About The Study: The findings of this study suggest an association between semaglutide, a glucagon-like peptide 1 receptor agonist, and nonarteritic anterior ischemic optic neuropathy. As this was ...

Study suggested that constant use of Semaglutide may be linked to development of a condition called non-arteritic ischemic ...

According to the team of researchers, semaglutide, which is the active ingredient in weight loss drugs Ozempic and Wegovy, ...

The risk of developing non-arteritic anterior ischemic optic neuropathy is four times higher for diabetics on semaglutide and seven times higher for people taking the drug to lose weight ...

Over a mean follow-up of nearly 3 years, patients with diabetes on semaglutide had more than a fourfold higher risk for developing nonarteritic anterior ischemic optic neuropathy (NAION ...

Study suggests Semaglutide a popular antidiabetic drug may be linked to vision loss Learn about the potential risks and ...

A recent study published in the journal JAMA Ophthalmology evaluated associations between semaglutide and the risk of non-arteritic anterior ischemic optic neuropathy (NAION). NAION is a ...

People taking semaglutide may have a higher risk of developing a rare "eye stroke" that can result in vision loss. Diabetes, ...